BIONOTE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,175 KRW | -0.83% |
|
-1.18% | -1.65% |
| 2023 | BioNote, Inc.(KOSE:A377740) added to S&P Global BMI Index | CI |
| 2023 | SD Biosensor, Inc announced that it has received KRW 226.0893359 billion in funding from BioNote, Inc. | CI |
| Sales 2022 | 480B 351M 29.17B | Sales 2023 | 90.08B 65.94M 5.48B | Capitalization | 433B 317M 26.35B |
|---|---|---|---|---|---|
| Net income 2022 | 308B 225M 18.72B | Net income 2023 | -20.5B -15M -1.25B | EV / Sales 2022 | 0.32 x |
| Net cash position 2022 | 720B 527M 43.8B | Net cash position 2023 | 395B 289M 24.04B | EV / Sales 2023 | 0.42 x |
| P/E ratio 2022 |
2.63
x | P/E ratio 2023 |
-21.1
x | Employees | 313 |
| Yield 2022 |
5.71% | Yield 2023 |
4.71% | Free-Float | 14.67% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.83% | ||
| 1 week | -1.18% | ||
| Current month | +1.46% | ||
| 1 month | +1.83% | ||
| 3 months | -8.94% | ||
| 6 months | -1.42% | ||
| Current year | -1.65% |
1 week
4 155.00
4 470.00
1 month
4 025.004 470.00
Current year
3 865.004 820.00
1 year
3 800.006 460.00
3 years
3 800.0011 700.00
5 years
3 800.0011 700.00
10 years
3 800.0011 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
Young-Sik Cho
CHM | Chairman | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Young-Sik Cho
CHM | Chairman | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/24/24 | 4,175 | -0.83% | 47,586 |
| 23/24/23 | 4,210 | -0.71% | 48,535 |
| 22/24/22 | 4,240 | 0.00% | 23,879 |
| 21/24/21 | 4,240 | -0.24% | 34,270 |
| 20/24/20 | 4,250 | +0.59% | 130,522 |
End-of-day quote Korea S.E., May 24, 2024
More quotes
BioNote Inc is a Korea-based company mainly engaged in the bio-contents business. The Company is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The Company is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -1.65% | 312M | |
| -5.56% | 181B | |
| -0.11% | 108B | |
| -6.17% | 66.12B | |
| +2.64% | 50.65B | |
| +6.58% | 43.66B | |
| +4.91% | 41.3B | |
| +21.98% | 31.6B | |
| +14.45% | 25.03B | |
| -5.81% | 24.16B |
- Stock Market
- Equities
- A377740 Stock
